Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15069672 | 1.00 | HSPB1 (0.39) | HSPB1BRD4MAPK14LPLLIPG | |
| SCHEMBL20155072 | 0.90 | MEN1 (0.40) | HSPB1LPLLIPGALDH1A1EGFR | |
| SCHEMBL20160238 | 0.88 | SLC6A4 (0.38) | BRD4LPLLIPGPTGS2EGFR | |
| SCHEMBL20155409 | 0.87 | SLC6A2 (0.39) | PTGS2ALDH1A1EGFR | |
| SCHEMBL20155416 | 0.87 | SLC6A2 (0.40) | LPLLIPGALDH1A1EGFR | |
| SCHEMBL20155120 | 0.86 | ALDH1A1 (0.40) | HSPB1BRD4LPLLIPGTRPA1 | |
| SCHEMBL21904898 | 0.85 | LPL (0.41) | HSPB1MAPK14LPLLIPGALDH1A1 | |
| SCHEMBL20155663 | 0.85 | HSPB1 (0.36) | HSPB1LPLLIPGTRPA1PTGS2 | |
| SCHEMBL20155469 | 0.84 | KDM4E (0.42) | LPLLIPGALDH1A1 | |
| SCHEMBL21904915 | 0.83 | HSPB1 (0.39) | HSPB1BRD4MAPK14LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023088493-A1 | FURO-PYRIDONE COMPOUND AND USE THEREOF | 中国科学院广州生物医药与健康研究院 | 2023-05-25 | — | — | WO | disclosed |
| EP-4143166-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | Nuvation Bio Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-112424200-B | Iminosulfones compound as bromodomain protein inhibitor, pharmaceutical composition and medical application thereof | 正大天晴药业集团股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220213122-A1 | SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS | NUVATION BIO INC (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3997070-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | Nuvation Bio Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114286818-A | Heterocyclic compounds as BET inhibitors | 诺维逊生物股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213122-A1 | SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS | BET1, BRD4, BRD3 | HSPB1 606/4885BRD4 2/4885MAPK14 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.